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Abstract
Introduction Suppression of Bcl-2 expression can overcome
cellular resistance to apoptosis induced by the adenovirus type
5 gene E1A in models of ovarian and breast cancer. Celecoxib,
a cyclooxygenase-2 (COX-2) inhibitor, is known to
downregulate Bcl-2 expression. We hypothesized that
celecoxib would enhance E1A-induced apoptosis by
suppressing Bcl-2 through suppressing COX-2 expression. If
successful, this strategy could represent a means of overcoming
resistance to E1A gene therapy.
Methods We first established the cytotoxicity of celecoxib in
two COX-2-overexpressing E1A-transfected breast cancer cell
lines (MDA-MB-231 and MDA-MB-435) and in two low-COX-2-
expressing E1A-transfected cell lines (MCF-7 (breast cancer)
and SKOV3.ip1 (ovarian cancer)). We next tested whether
higher sensitivity to celecoxib among these cell lines resulted
from increased apoptosis by flow cytometry and western
blotting. We further investigated whether suppression of Bcl-2
by celecoxib was involved in the apoptosis resulting from
celecoxib treatment, and we explored whether the celecoxib-
induced apoptosis in these cells depends on a COX-2
downstream pathway.
Results The two COX-2-overexpressing cell lines MDA-MB-
231-E1A and MDA-MB-435-E1A were more sensitive to
celecoxib than the corresponding control cells, but the two low-
COX-2-expressing cell lines MCF-7-E1A and SKOV3.ip1-E1A
were no more sensitive than control cells to celecoxib.
Therefore, we used the MDA-MB-231-E1A and MDA-MB-435-
E1A cells for all further experiments. In both cell lines, sub-G1
fraction was increased, or cleavage of PARP and caspase-9
were increased after 5 days of exposure to 40 μM celecoxib.
However, Bcl-2 was suppressed only in the MDA-MB-435-E1A
cells and not in the MDA-MB-231-E1A cells. Restoring Bcl-2
expression in the MDA-MB-435-E1A stable transfectants did
not affect their sensitivity to celecoxib. However, adding
prostaglandin E2 (PGE2) or PGF2α blunted the sensitivity to
celecoxib of both E1A stable transfectants.
Conclusion We speculate that one mechanism by which
celecoxib enhances E1A-induced apoptosis in cells that
express high levels of COX-2 is through blocking PGE2 or
PGF2α.
Introduction
The adenovirus type 5 gene E1A is being developed as a ther-
apeutic agent for breast, head and neck, and ovarian cancer
[1-3]. The tumor-suppressive effect of E1A results from its
induction of apoptosis, its inhibition of invasion and metasta-
sis, and its suppression of proliferation [4]. Although the mech-
anism by which E1A induces apoptosis is not completely
understood, accumulating evidence suggests that E1A exerts
its apoptotic effect through several pathways. One such path-
way involves binding of E1A to the retinoblastoma protein,
which results in the release and activation of transcription fac-
tor E2F [4-6]. Activated E2F can induce apoptosis through
p53-dependent and p53-independent pathways [7-9]. E1A is
also known to induce apoptosis through p53-dependent and
p53-independent pathways [10]. Several factors that modu-
late E1A-induced apoptosis have been reported, includingPage 1 of 10
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sis-inducing ligand (TRAIL) [13] or TRAIL accompanied by
caspase activation [14], activation of the pro-apoptotic factor
p38 or inactivation of Akt/PKB [15], inhibition of nuclear fac-
tor-kappa B [16], and suppression of the Axl-Gas6 interaction
[17].
However, E1A does not induce apoptosis efficiently in all
types of cancer cells. The reason for this is unclear but could
reflect the existence of a resistance mechanism or the onco-
genic effects of the E1A gene. We recently showed that
resistance to E1A gene therapy in an ovarian cancer xenograft
model could be overcome by downregulating Bcl-2 with a Bcl-
2 antisense oligonucleotide [18]. Bcl-2 inhibits apoptosis by
inhibiting the release of cytochrome c and the activation of
caspase-9 in E1A-transfected cells. Bcl-2 was the only major
mechanism blocking E1A-induced apoptosis in our previous
model. Theoretically, a means of downregulating Bcl-2 would
overcome resistance to the apoptosis induced by E1A gene
therapy. Because the US Food and Drug Administration has
yet to approve Bcl-2 antisense oligonucleotide for clinical use,
we are exploring other drugs that can also downregulate Bcl-
2. Recent reports that cyclooxygenase-2 (COX-2) inhibitors
could induce apoptosis through Bcl-2 downregulation led us
to consider the role of COX-2 inhibitors in the E1A-induced
apoptosis of cancer cells. In those reports, the selective COX-
2 inhibitor NS-398 was found to downregulate Bcl-2 in
LNCaP prostate cancer cells [19]; another COX-2 inhibitor,
celecoxib, downregulated Bcl-2 in K562 chronic myeloid
leukemia cells [20] and in MPP89 malignant mesothelioma
cells [21]. In vivo investigations have shown that Bcl-2 down-
regulation by COX-2 inhibitors is accompanied by downregu-
lation of the COX-2 protein. In one study of mice implanted
with the hepatoma cell line H22, treatment with the COX-2
inhibitor nimesulide led to reductions in both COX-2 and Bcl-
2 expression [22]. Similarly, celecoxib also reduced both
COX-2 and Bcl-2 expression in an MTag mouse model of
breast cancer [23]. Conversely, another group has proposed
that COX-2 overexpression increases resistance to apoptosis
through the upregulation of Bcl-2 [24]. Still others have shown
that forced COX-2 overexpression or treatment with prostag-
landins induces Bcl-2 expression [25,26]. Collectively, these
reports suggest that COX-2 is upstream of Bcl-2 and led us to
propose that suppressing COX-2 expression with the COX-2
inhibitor celecoxib will suppress Bcl-2 expression, thereby
enhancing E1A-induced apoptosis. If successful, this strategy
could represent a means of overcoming resistance to E1A
gene therapy.
Materials and methods
Cell lines and reagents
Three human breast cancer cell lines (MDA-MB-231, MDA-
MB-435, and MCF-7) and one ovarian cancer cell line
(SKOV3.ip1, a subline of SKOV3 cells) were maintained in
Dulbecco's modified Eagle's medium/Ham's F-12 medium
(DMEM/F12; Gibco-BRL, Grand Island, NY, USA) supple-
mented with 10% fetal bovine serum and penicillin/streptomy-
cin, and maintained in a humidified atmosphere of 5% CO2 at
37°C. The parental cell lines, the vector only transfection con-
trol cells, and the E1A-transfected cells were all kindly pro-
vided by Dr Mien-Chie Hung (The University of Texas M D
Anderson Cancer Center, Houston, TX, USA) [15,27,28]. The
E1A stable transfectants were selected by growing them in
DMEM/F12 medium containing 500 μg/ml G418. All experi-
ments were conducted under the guidelines of the M D Ander-
son Cancer Center.
Celecoxib (LKT Laboratories, St Paul, MN, USA) was dis-
solved in dimethylsulfoxide to 100 mM and stored at -20°C.
For the cell culture experiments, celecoxib was diluted with
DMEM/F12 in various concentrations. The final concentration
of dimethylsulfoxide in the DMEM/F12 medium was kept at
less than 0.1%. PGE2 and PGF2α (Cayman Chemical, Ann
Arbor, MI, USA) were dissolved in dimethlysulfoxide to 10 mM
and stored at -20°C.
Cell viability assays
Cell viability was assessed with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) [29] and trypan blue
exclusion assays. For the MTT assay, cells were plated in 96-
well plates (1.2 × 104 cells/well for MDA-MB-231 cells or 8.0
× 103 cells/well for MDA-MB-435, MCF-7, and SKOV3.ip1
cells) in 80 μl of medium and incubated for 24 h. Then, 20 μl
of fresh medium containing celecoxib at 0–300 μM were
added to each well, resulting in final celecoxib concentrations
of 0–60 μM in five sequential dilutions. After cells had been
cultured with celecoxib for 3 or 5 days, MTT (Sigma Chemical
Co., St Louis, MO, USA) was added to a final concentration of
1 mg/ml. Reaction mixtures were incubated for 3 h. The result-
ing crystals were dissolved in dimethlysulfoxide (200 μl), and
optical density was measured at 570 nm with a microplate
reader (Bio-Rad Laboratories, Hercules, CA, USA).
We also used a trypan blue exclusion assay to confirm cell via-
bility during treatment with 40 μM celecoxib, because the via-
bility varied greatly among cell types. For that assay, MDA-MB-
231 cells (4 × 105) or MDA-MB-435 cells (2 × 105) were
plated in six-well plates in 2 ml of DMEM/F12 and incubated
for 24 h. Then, 500 μl of fresh medium containing 200 μM
celecoxib was added to each well, resulting in a final concen-
tration of 40 μM, and the cells were incubated for 5 days. To
determine the effect of PGE2 or PGF2α on celecoxib sensitivity,
exogenous PGE2 or PGF2α (10 μM) was added to the
celecoxib solution. After being cultured with celecoxib in the
presence or absence of PGE2 or PGF2α for 5 days, cells were
harvested by trypsinization and incubated with 0.4% trypan
blue (Sigma). Cell viability was calculated as the percentage
of viable (nonstaining) cells.Page 2 of 10
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For flow-cytometric analysis of apoptosis, cells were harvested
by trypsinization, washed twice with ice-cold PBS, and fixed
with cold 70% ethanol at -20°C overnight. The fixed cells were
washed twice with PBS and suspended in 1 ml of PBS con-
taining Tween-20 (0.5%), RNase (10 μg/ml), and propidium
iodide (10 μg/ml). The sub-G1 (apoptotic) cell population was
measured with a FACScan cytofluorometer (Becton Dickin-
son, San Jose, CA, USA).
Western blotting
For western blot analyses, cells were washed with PBS and
lysed in lysis buffer (20 mM Na2PO4, 150 mM NaCl, 1% Triton
X-100, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 100
mM NaF, and 2 mM Na3VO4) as described previously [18].
Proteins were separated by polyacrylamide gel electrophore-
sis on a sodium dodecyl sulfate-polyacrylamide gel and trans-
ferred to a polyvinylidene difluoride membrane (Bio-Rad).
Membranes were incubated with primary antibodies specific
for COX-2 (1:1000; Cayman Chemical); Bcl-2 (1:500) and
E1A (1:500) (both from BD PharMingen); poly-ADP ribosome
polymerase (PARP) (1:1000) and cleaved caspase-9 (1:200)
(both from Cell Signaling Technology, Beverly, MA, USA); cas-
pase-8 (1:200) (from Oncogene Research Products, San
Diego, CA, USA); and actin (1:5000) (Sigma). Then, mem-
branes were incubated with fluorescent-conjugated mouse
(1:5000) or rabbit (1:5000) secondary antibodies (IRdye; Li-
Cor Biosciences, Lincoln, NE, USA). The membranes were
scanned and relative protein expression levels estimated by
using an Odyssey western blotting system (Li-Cor Bio-
sciences). Downregulation was defined as a protein expres-
sion level at least 20% less than that of the control (untreated)
cells.
Bcl-2 transfections
The Bcl-2 expression vector was constructed by inserting Bcl-
2 cDNA at the EcoRI site of the pCl-neo mammalian expres-
sion vector (Promega, Madison, WI, USA). Briefly, MDA-MB-
435 cells (4 × 105) were cultured for 24 h in six-well plates in
1 ml/well of DMEM/F12 with 10% fetal bovine serum until 60–
70% confluence. The next day, the liposomal vector of the SN
gene delivery system [30] was incubated with Bcl-2 DNA at a
ratio of 4 μg DNA: 5 μl SN in 100 μl Opti-MEM in each well
and added to the cultures. Bcl-2-overexpressing cells and
control cells were plated 24 h later and tested for viability with
a trypan blue exclusion assay as described above.
Prostaglandin analyses
MDA-MB-231-E1A cells (4 × 105) or MDA-MB-435-E1A cells
(2 × 105) were plated in six-well plates in 2 ml of DMEM/F12,
incubated for 24 h, and treated with celecoxib (0–40 μM) for
120 h. At that time, cellular supernatants were collected and
analyzed for PGE2 and PGF2α by enzyme-linked immunosorb-
ent assay (Cayman Chemical) according to the manufacturer's
instructions.
Statistical analyses
Two-tailed paired t-tests were used to compare data between
groups. P < 0.05 was considered to be statistically significant.
Data were expressed as means ± SD of at least three inde-
pendent experiments, each of which was run in quadruplicate.
Results
COX-2 expression in E1A-transfected breast and ovarian 
cancer cell lines
We first investigated the expression of COX-2 protein in three
breast cancer cell lines (MDA-MB-231, MDA-MB-435, and
MCF-7) and an ovarian cancer cell line (SKOV3.ip1), all stably
transfected with E1A, to determine the relationship between
COX-2 protein expression level and sensitivity to celecoxib.
Western blot analyses showed that COX-2 expression was
highest in the MDA-MB-231-E1A transfectants, followed
closely by the MDA-MB-435-E1A transfectants. By contrast,
COX-2 expression was low in the SKOV3.ip1-E1A and MCF-
7-E1A transfectants (Figure 1A). If the COX-2 expression level
of the MDA-MB-231-E1A stable transfectants is considered
to be 100%, the relative percentage COX-2 expression for
each stable transfectant is as follows: MDA-MB-435-E1A,
78%; SKOV3.ip1-E1A, 6%; and MCF-7-E1A, 6%. Thus, we
defined MDA-MB-231-E1A and MDA-MB-435-E1A stable
transfectants as high-COX-2-expressing cell lines, and
SKOV3.ip1-E1A and MCF-7-E1A stable transfectants as low-
COX-2-expressing cell lines.
To rule out the possibility that E1A transfection affects COX-
2 expression levels, we compared COX-2 levels in E1A stable
transfectants with that in the corresponding vector control
cells by western blotting analysis. If the COX-2 expression lev-
els of each E1A transfectant is defined as 100%, the corre-
sponding COX-2 expression levels of the vector controls were
as follows: 65% for MDA-MB-231, 144% for MDA-MB-435,
71% for SKOV3.ip1 and 67% for MCF-7 (Figure 1B). Thus,
we found that E1A transfection did not consistently affect
COX-2 expression levels in these cell lines.
Celecoxib induces apoptosis in MDA-MB-231-E1A and 
MDA-MB-435-E1A stable transfectants
After establishing the relative amounts of COX-2 protein
expressed by the E1A stable transfectants, we investigated
whether those transfectants were more sensitive to celecoxib
than their respective controls by using an MTT assay. The
high-COX-2-expressing MDA-MB-231-E1A and MDA-MB-
435-E1A cells were more sensitive to celecoxib (after 5 days
of exposure to 0–60 μM) than the vector control or parental
control cells (Figure 2A). By contrast, the low-COX-2-express-
ing cells (SKOV3.ip1 and MCF-7) showed no difference in
celecoxib sensitivity between the E1A transfectants and the
controls (Figure 2B).
To quantitatively compare differences in sensitivity to
celecoxib among cells, we tested the MDA-MB-231-E1A andPage 3 of 10
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trypan blue assay. After a 5-day exposure to 40 μM celecoxib,
the MDA-MB-231-E1A cells were significantly more sensitive
(mean 23.8% ± SD 2.2% viable cells) than the MDA-MB-231
vector control cells (82.3% ± 3.9%) (P = 0.0002) or the MDA-
MB-231 parental cells (82.0% ± 1.4%) (P < 0.0001). Simi-
larly, the MDA-MB-435-E1A stable transfectants were more
sensitive to celecoxib (27.2% ± 1.2% viable cells) than the
MDA-MB-435 vector control cells (91.2% ± 0.5%) (P <
0.0001) or the MDA-MB-435 parental cells (93.9% ± 3.5%)
(P < 0.0001) (Figure 2C). We then investigated whether
these differences in viability had been caused by apoptosis by
using flow cytometry. A 5-day exposure to 40 μM celecoxib
increased the sub-G1 fraction from 9.1% to 25.7% in MDA-
MB-231-E1A cells and from 8.2% to 37.1% in MDA-MB-435-
E1A cells (Figure 3A), indicating increases in apoptosis. We
also tested cleavage of PARP, caspase-8, and caspase-9 as
other indicators of apoptosis. Celecoxib treatment led to the
disappearance of uncleaved PARP (116 kDa) in both cell
lines; it also led to the appearance of cleaved PARP (89 kDa)
in MDA-MB-435-E1A cells and the appearance of cleaved
PARP expression in MDA-MB-231-E1A cells (Figure 3B).
Celecoxib treatment also led to increases in cleaved caspase-
9 (37 kDa) levels in both MDA-MB-231-E1A and MDA-MB-
435-E1A transfectants but did not affect levels of cleaved cas-
pase-8 (28 kDa). These results suggest that celecoxib treat-
ment (5 days at 40 μM) induced apoptosis in MDA-MB-231
and MDA-MB-435 cells stably transfected with E1A.
Celecoxib downregulates COX-2 protein expression in 
MDA-MB-231 and MDA-MB-435 cells
Evidence that nonsteroidal anti-inflammatory drugs can sup-
press COX-2 by transcriptional regulation [31] as well as sup-
pressing both COX-2 and Bcl-2 protein expression [22,23]
led us to investigate whether celecoxib would change the
amount of COX-2 protein expressed by MDA-MB-231 and
MDA-MB-435 cells. Indeed, COX-2 protein expression was
downregulated in all MDA-MB-231 cell variants; the percent-
age decreases were 32% for the MDA-MB-231 parental cells,
34% for the vector control cells, and 58% for the E1A stable
transfectants (Figure 4A). COX-2 protein expression was also
decreased in all MDA-MB-435 variants, with the percentages
being 39% for MDA-MB-435 parental cells, 25% for the vec-
tor control cells, and 60% for the E1A stable transfectants
(Figure 4A). In both MDA-MB-231 and MDA-MB-435 cells,
COX-2 was suppressed to a greater extent in the E1A trans-
fectants than in the corresponding parental or vector control
cells. These results suggest that celecoxib-induced apoptosis
in cells expressing E1A involves the suppression of COX-2.
Bcl-2 suppression does not contribute to celecoxib-
induced apoptosis in E1A stable transfectants
Next, we investigated whether suppression of Bcl-2 by
celecoxib is involved in the apoptosis resulting from celecoxib
treatment. After a 5-day treatment with 40 μM celecoxib, Bcl-
2 levels in the MDA-MB-435 cells were decreased (by 27%)
only in the E1A transfectant; Bcl-2 level did not change in any
of the MDA-MB-231 variants (Figure 4A). In timecourse exper-
iments with the same celecoxib concentration (40 μM), Bcl-2
was suppressed by 37% at 72 h and by 52% at 96 h in MDA-
MB-435-E1A cells. However, Bcl-2 was not suppressed at
either measurement time in the MDA-MB-231-E1A cells (Fig-
ure 4B).
Figure 1
COX-2 protein expression in breast and ovarian cancer cell lines stably transfected with E1A
transfected with E1A. (a) MDA-MB-231-E1A stable transfectants pro-
duced the greatest amounts of COX-2; MDA-MB-435-E1A cells pro-
duced 78% of that amount, but the SKOV3.ip1-E1A and MCF-7-E1A 
cells produced only 6% of that amount. MDA-MB-231-E1A cells 
expressed slightly more E1A than the other three cell lines. (a) COX-2 
protein expression level between the E1A stable transfectants and their 
corresponding vector control cells or parent cells. If the COX-2 expres-
sion levels of each E1A transfectant is defined as 100%, the corre-
sponding COX-2 expression levels of the vector controls were as 
follows: 65% for MDA-MB-231, 144% for MDA-MB-435, 71% for 
SKOV3.ip1 and 67% for MCF-7.Page 4 of 10
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pression to celecoxib-induced apoptosis, we transfected Bcl-
2 DNA into the MDA-MB-435 variants (Figure 4C) to see if
restoring Bcl-2 expression would affect sensitivity to
celecoxib. Bcl-2 restoration did not affect the viability of MDA-
MB-435-E1A stable transfectants after a 5-day treatment with
40 μM celecoxib (Figure 4D). These results suggest that
celecoxib induces apoptosis in MDA-MB-231-E1A and MDA-
MB-435-E1A stable transfectants regardless of Bcl-2
expression.
Celecoxib enhances apoptosis of MDA-MB-231-E1A and 
MDA-MB-435-E1A cells via prostaglandins E2 or F2α
Given our findings that celecoxib induced apoptosis in the
E1A stable transfectants and that COX-2 downregulation is
involved in this apoptosis but Bcl-2 suppression is not, we next
Figure 2
Celecoxib decreases the viability of MDA-MB-231-E1A and MDA-MB-435-E1A stable transfectantsi ilit  f - - -  and DA- B-435-E1A stable transfectants. (b) MTT assays after a 5-day exposure to 0–60 
μM celecoxib indicate substantial reductions in cell viability in all variants of the MDA-MB-231 and MDA-MB-435 cell lines (E1A stable transfect-
ants, vector control, and parental control cells). Each point represents means from tests performed in quadruplicate; the bars are standard devia-
tions. In both cell lines, the E1A transfectants were more sensitive than the vector control or parental control cells. (b) MTT assays in all variants of 
the SKOV3.ip1 and MCF-7 cell lines. The E1A transfectants have no difference to sensitivity for celecoxib in both cell lines. (c) Trypan blue assays 
after a 5-day exposure to 40 μM celecoxib show substantial reductions in viability of MDA-MB-231 and MDA-MB-435 cells. Values shown are nor-
malized to the viability of the control (untreated) cells. Each bar represents means from tests performed in quadruplicate; bars are standard devia-
tions. P values are from two-tailed paired t tests.Page 5 of 10
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cells depends on a pathway downstream of COX-2. For these
experiments, we tested the effects of a 5-day treatment with
40 μM celecoxib on cell viability with or without the addition of
10 μM prostaglandin (PG) E2 or PGF2α, two molecules
located downstream of COX-2. In the MDA-MB-231-E1A
cells, treatment with celecoxib alone produced a mean of
35.9% viable cells (± 2.7% SD); the addition of either
prostaglandin substantially improved cell viability (62.1% ±
3.9% viable cells for PGE2 (P = 0.0005), 63.0% ± 3.8% for
PGF2α (P = 0.0026). Results were similar for the MDA-MB-
435-E1A cells (33.3% ± 7.5% for celecoxib only, 58.6% ±
7.7% for PGE2 (P = 0.041), and 60.2% ± 6.7% for PGF2α (P
= 0.0030)) (Figure 5). These results suggest that celecoxib
enhances apoptosis of cells that stably express E1A in part by
blocking PGE2 or PGF2α.
To test the effect of celecoxib on prostaglandin synthesis, we
assessed PGE2 and PGF2α levels in MDA-MB-231-E1A and
MDA-MB-435-E1A cells treated for 5 days with 40 μM
celecoxib (data not shown). Enzyme-linked immunosorbent
assay showed that in the MDA-MB-231-E1A cells, celecoxib
treatment significantly inhibited PGE2 (mean ± SD 0.20 pg/ml
± 0.08 pg/ml vs 2.16 pg/ml ± 1.25 pg/ml for dimethylsulfoxide
control; P = 0.002), but celecoxib had no effect on PGE2 syn-
thesis in the MDA-MB-435-E1A cells. Conversely, celecoxib
inhibited PGF2α in MDA-MB-435-E1A cells (121.7 pg/ml ±
12.3 pg/ml vs 173.6 pg/ml ± 7.4 pg/ml for control, P = 0.003)
but did not affect PGF2α synthesis in MDA-MB-231-E1A cells.
Discussion
Our hypothesis was that celecoxib would enhance E1A-
induced apoptosis by suppressing COX-2 expression and
thereby suppressing Bcl-2 expression. In exploring the possi-
bility that the COX-2 inhibitor celecoxib would downregulate
Bcl-2, we found that celecoxib did enhance E1A-induced
apoptosis in cells that express high levels of COX-2 protein.
We also found that PGE2 or PGF2α are involved in this
Figure 3
Celecoxib enhances apoptosis of MDA-MB-231-E1A and MDA-MB-435-E1A stable transfectants. (a) Cell cycle distribution of MDA-MB-231-E1A 
and MDA-MB-435-E1A cells was detected by fluorescence-activated cell sorting after a 5-day exposure to 0 or 40 μM celecoxib. The percentage of 
cells in sub-G1 (apoptosis) appears at the upper right of each graph. (b) Western blots of MDA-MB-231 and MDA-MB-435 cells treated with 0 or 
40 μM celecoxib for 5 days and tested for cleaved caspase-9 (cl-cas-9), uncleaved and cleaved caspase-8 (cl-cas-8), PARP (uncleaved and 
cleaved), E1A, and actin. Cleaved PARP and cleaved caspase-9 levels were higher after celecoxib treatment in the MDA-MB-231-E1A and MDA-
MB-435-E1A stable transfectants, but expression of cleaved caspase-8 (cl-cas-8) did not change.Page 6 of 10
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did not depend on suppression of Bcl-2.
With regard to suppression of Bcl-2 by COX-2 inhibitors,
some previous studies have shown that the ability of COX-2
inhibitors to induce apoptosis in cancer cells depends on the
downregulation of Bcl-2 [19-23]. However, others have
reported that COX-2 inhibitors can induce apoptosis in cancer
cells independently of Bcl-2 [29,32]. Cao and Prescott [33]
proposed that Bcl-2 overexpression is probably caused by
reductions in arachidonic acid and increases in PGE2 levels.
Nevertheless, our finding that COX-2 suppression did not sup-
press Bcl-2 leads us to propose that other mechanisms exist
by which celecoxib induces apoptosis, at least in the breast
cancer cell lines we tested. In other words, it is unclear how
much suppression of Bcl-2 is enough to induce significant
apoptosis, or, indeed, if celecoxib has the capacity to down-
regulate Bcl-2. It is possible that only the reduction in Bcl-2 led
to apoptosis in the MDA-MB-435-E1A stable transfectants;
however, that reduction would have to have been substantial.
We showed that 40 μM of celecoxib was enough to enhance
E1A-induced apoptosis in MDA-MB-231-E1A and MDA-MB-
Figure 4
Celecoxib downregulated COX-2 protein expression in all MDA-MB-231 and MDA-MB-435 variants, but celecoxib downregulated Bcl-2 expression in only the MDA-MB-435-E1A stable ra sfectants
in only the MDA-MB-435-E1A stable transfectants. (a) Western blots of MDA-MB-231 and MDA-MB-435 cells treated with 0 or 40 μM celecoxib 
for 5 days and tested for COX-2 and Bcl-2. Percentages indicate differences relative to the 0 μM control samples. Protein expression was consid-
ered to be downregulated if the treated condition was at least 20% less than the control (untreated) condition. (b) Time course of Bcl-2 expression 
after treatment with 0 or 40 μM celecoxib in MDA-MB-435-E1A and MDA-MB-231-E1A stable transfectants. Bcl-2 was suppressed at both 72 and 
96 h in the MDA-MB-435-E1A stable transfectants but was not suppressed in the MDA-MB-231-E1A stable transfectants. (c) Transfection of MDA-
MB-435 cells with Bcl-2 DNA (+) or a control DNA (-) led to overexpression of Bcl-2 in all variants. (d) MDA-MB-435-E1A cells made to overexpress 
Bcl-2 and non-Bcl-2-overexpressing cells were treated with 0 or 40 μM celecoxib for 5 days, and cell viability was determined with a trypan-blue 
assay. Bcl-2 overexpression did not restore sensitivity to celecoxib (P = 0.11).Page 7 of 10
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sion. This result suggests that other molecules than Bcl-2
could be critical for celecoxib to enhance E1A-induced
apoptosis.
We then investigated the involvement of PGE2 or PGF2α, two
molecules located downstream of COX-2. The synthesis of
prostaglandins is known to depend on COX-2 activity. In one
study, the synthesis of PGE2 or PGF2α was enhanced by the
overexpression of COX-2 in the mammary glands of COX-2
transgenic mice [34]. In addition, PGF2α has been shown to
promote tumorigenesis in endometrial cancer cells [35].
Several reports indicate that the reduction of COX-2 inhibits
the release of prostaglandins. For example, treatment of the
COX-2-overexpressing myeloma cell line ARH-77 with
indomethacin led to the reduction of PGD2, PGE2, and PGF2α
[36]. Celecoxib has been shown to inhibit the release of PGE2
or PGF2α from ureteral segments in swine [37]. NS-398 inhib-
ited the production of prostaglandins, including PGD2, PGE2
and PGF2α, in the prostate cancer cell line PC-3 [38]. We
speculate that both PGE2 and PGF2α derived from COX-2
could be key factors in modulating the apoptotic effect in E1A-
transfected cell lines. Indeed, we found that blocking PGE2
and PGF2α production was crucial for celecoxib-induced
apoptosis in the E1A stable transfectants. We confirmed here
that both PGE2 and PGF2α influenced apoptosis, but
celecoxib suppressed different prostaglandins in the two dif-
ferent cell lines. This difference could reflect the involvement
of other pathways that modulate apoptosis in E1A-transfected
cell lines.
Davis et al. [39] reported that the COX-2 inhibitor NS-398
was more cytotoxic in a prostate epithelial cell line in which
E2F1 had been activated than in the original prostate epithelial
cell lines, speculating that the reason for the greater cytotoxic-
ity was a disruption in the retinoblastoma/E2F complexes. We
showed that caspase-9 and PARP were activated, but cas-
pase-8 was not activated, in celecoxib-treated MDA-MB-231-
E1A and MDA-MB-435-E1A stable transfectants (Figure 3B).
These findings are consistent with others showing that
celecoxib enhances caspase-3 or caspase-9 activation
through PGE2 inhibition [42,43]. We speculate that PGE2 or
PGF2α (or both) inhibit intrinsic apoptotic pathway induced by
E1A. This speculation is, to the best of our knowledge, the first
to link PGE2 or PGF2α in the apoptosis associated with E1A.
Generally speaking, COX-2 inhibitors, including celecoxib, are
thought to block prostaglandin synthesis by inhibiting the
enzymatic activity of COX-2. However, COX-2 inhibitors
(including celecoxib) might also act by suppressing produc-
tion of the COX-2 protein [31,44,45]. We showed that the
celecoxib-sensitive MDA-MB-231-E1A and MDA-MB-435-
E1A stable transfectants originally overexpressed COX-2, and
they produced less COX-2 protein in the presence of
celecoxib (Figures 1 and 4A). Our finding that COX-2 levels
were highest in the MDA-MB-231-E1A cells was confirmed by
others' reports that the MDA-MB-231 cell line expresses high
levels of COX-2 [46-48]. Moreover, our findings regarding
sensitivity to celecoxib imply that celecoxib inhibited the pro-
duction of prostaglandins not only by inhibiting COX-2 enzy-
matic activity but also by modulating COX-2 protein
expression. A previous report indicated that modulating COX-
2 protein expression with a structural analog of celecoxib (sc-
236) or with the pharmacologic COX-2 protein-suppressing
agent curcumin affected apoptosis in the COX-2-positive
colon cancer cell line HT-29 [49]; another report showed that
modulating COX-2 protein expression with the retinoid X
receptor-selective retinoid LGD1069 decreased PGE2 pro-
Figure 5
Celecoxib-induced apoptosis of MDA-MB-231-E1A and MDA-MB-435-E1A cells depends on PGE2 or PGF2α. Treatment of MDA-MB-231-E1A 
and MDA-MB-435-E1A stable transfectants with 0 or 40 μM celecoxib (CLX) plus 10 μM of either PGE2or PGF2α for 5 days blunted sensitivity to 
celecoxib in both cell lines.Page 8 of 10
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speculate that the modulation of COX-2 protein expression by
celecoxib is a significant part of its effect in reducing prostag-
landin levels.
Our study had some limitations. For one thing, although we did
confirm that all four E1A stable transfectants expressed E1A
(Figure 1), the level of expression was not uniform among the
cell lines. Specifically, MDA-MB-231-E1A cells expressed
slightly more E1A than the other three cell lines, a result that
has also been shown by others [15,28]. Thus, we were not
able to exclude the possibility that E1A expression level could
affect sensitivity to celecoxib. In addition, we examined only
one COX-2 inhibitor, celecoxib. COX-2 inhibitors other than
celecoxib can downregulate Bcl-2 [19,22]; whether other
COX-2 inhibitors would downregulate Bcl-2 expression to a
greater extent than celecoxib remains to be seen. Elucidation
of the precise mechanism by which COX-2 inhibitors down-
regulate Bcl-2 will help to clarify the appropriate uses of COX-
2 inhibitors in preclinical settings for treating cancer.
Conclusion
We found that celecoxib enhanced E1A-induced apoptosis in
breast cancer cells that express high levels of COX-2 protein
and that this effect depended, at least in part, on blocking the
production of PGE2 or PGF2α. Further studies exploring the
precise mechanism by which prostaglandins influence E1A-
induced apoptosis, and confirmation of synergistic effects
between E1A gene therapy and COX-2 inhibitor treatment in
cancer xenograft models, are needed to establish conclusively
that COX-2 inhibitors can overcome resistance to E1A-
induced apoptosis.
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